Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 in ozone-induced neutrophilia
NCT00920933Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in asthma, sponsored by Novartis. Started Jan 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00920933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920933.